Key takeaway
Stool metagenomics in 56 pairs of people with irritable bowel syndrome (IBS) and household controls found that 50% of IBS cases had a 'pathogenic-like' microbiome (IBS-P) and that this group responded better clinically to 4 weeks of a low FODMAP diet (p = 0.02). The diet follow-up covered only 41 pairs, with no comparison group on a normal diet, so the result is a hypothesis for further testing.
Study design
Research article
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Reducing FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) can ease IBS, but it is not clear how, or who benefits most. The authors looked for microbial signatures that predict response to the low FODMAP diet and asked whether shifts in gut bacteria and their functions explain how the diet works.
Who and how
Stool metagenomics gave detailed taxonomic and functional profiles of the gut microbiota in IBS cases and household controls (n=56 pairs) eating their usual diet. Clinical response and microbiota changes were then studied in 41 pairs after 4 weeks on a low FODMAP diet. Unsupervised analysis of baseline IBS microbiomes defined subtypes. The abstract does not report the symptom scale, or whether dietary adherence was verified.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Unsupervised analysis found two microbiota profiles in IBS cases: IBS-P (pathogenic-like), rich in Firmicutes and in genes for amino acid and carbohydrate metabolism but low in Bacteroidetes, and IBS-H (health-like), similar to controls.
- 2On the low FODMAP diet, IBS-H and control microbiota were unaffected, while the IBS-P signature moved toward a health-associated profile, with more Bacteroidetes (p = 0.009), fewer Firmicutes species (p = 0.004) and normalised primary metabolic genes.
- 3Clinical response to the diet was greater in IBS-P than in IBS-H (p = 0.02).
- 450% of IBS cases had the IBS-P signature.
Limits & uncertainty
- 1The study is small, with 56 case-control pairs at baseline and 41 after the diet, and the abstract gives no effect sizes or confidence intervals.
- 2There was no randomised comparison group staying on a usual diet, so symptom improvement cannot be separated from placebo effects or natural fluctuation.
- 3The subtypes came from an unsupervised analysis of the same people later studied for response, so the split may not replicate in other groups.
- 4The authors suggest, but do not show, that microbiota changes explain the benefit. This reading is based on the abstract only.
What to take from it
These findings hint that gut bacteria may help explain why a low FODMAP diet works for some people with IBS and not others, but there is no test you can use today to predict your response. A low FODMAP diet is restrictive, and it is best done with a dietitian and your clinician rather than on your own.
Reading your own data
Food and symptom logs are the practical link: recording what you eat, stool pattern and symptom severity daily lets you and a dietitian see whether a dietary change helps. A wearable cannot measure your gut microbiome, so rely on consistent logs over weeks rather than single bad days.
How to read this evidence
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Objective
Reducing FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) can be clinically beneficial in IBS but the mechanism is incompletely understood. We aimed to detect microbial signatures that might predict response to the low FODMAP diet and assess whether microbiota compositional and functional shifts could provide insights into its mode of action.
Design
We used metagenomics to determine high-resolution taxonomic and functional profiles of the stool microbiota from IBS cases and household controls (n=56 pairs) on their usual diet. Clinical response and microbiota changes were studied in 41 pairs after 4 weeks on a low FODMAP diet.
Results
Unsupervised analysis of baseline IBS cases pre-diet identified two distinct microbiota profiles, which we refer to as IBS^(P) (pathogenic-like) and IBS^(H) (health-like) subtypes. IBS^(P) microbiomes were enriched in Firmicutes and genes for amino acid and carbohydrate metabolism, but depleted in Bacteroidetes species. IBS^(H) microbiomes were similar to controls. On the low FODMAP diet, IBS^(H) and control microbiota were unaffected, but the IBS^(P) signature shifted towards a health-associated microbiome with an increase in Bacteroidetes (p=0.009), a decrease in Firmicutes species (p=0.004) and normalisation of primary metabolic genes. The clinical response to the low FODMAP diet was greater in IBS^(P) subjects compared with IBS^(H) (p=0.02).
Conclusion
50% of IBS cases manifested a 'pathogenic' gut microbial signature. This shifted towards the healthy profile on the low FODMAP diet; and IBS^(P) cases showed an enhanced clinical responsiveness to the dietary therapy. The effectiveness of FODMAP reduction in IBS^(P) may result from the alterations in gut microbiota and metabolites produced. Microbiota signatures could be useful as biomarkers to guide IBS treatment; and investigating IBS^(P) species and metabolic pathways might yield insights regarding IBS pathogenic mechanisms.
Sources & attribution
Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet.
Vervier K, Moss S, Kumar N, Adoum A, Barne M, Browne H, Kaser A, Kiely CJ, Neville BA, Powell N, Raine T, Stares MD, Zhu A, De La Revilla Negro J, Lawley TD, Parkes M.
Gut · 2021-11-22
DOI: 10.1136/gutjnl-2021-325177 ↗PubMed · 34810234 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

